Core Viewpoint - Carbon Revolution plc has initiated a planned Voluntary Administration for its Australian subsidiaries to restructure and emerge as a financially secure leader in lightweight wheel technology [2][3][5]. Group 1: Voluntary Administration and Restructuring - The Australian subsidiaries, including Carbon Revolution Pty. Ltd. and Carbon Revolution Operations Pty Ltd, have decided to enter Voluntary Administration [2]. - The restructuring aims to eliminate senior secured debt and legacy obligations, allowing the Australian subsidiaries to emerge as a stronger, privately-held business [5]. - A Restructuring Support Agreement (RSA) has been established with senior secured lenders to facilitate this financial restructure [5]. Group 2: Strategic Goals and Market Positioning - The restructuring is seen as an opportunity to create a de-leveraged balance sheet and enhance customer relationships [4]. - The restructured business will focus on unlocking the global market for lightweight wheels through a strategic Four Pillar Framework [6]. - The company anticipates re-emerging in Q2 2026 with the necessary capital and market positioning to execute its strategic plan [7]. Group 3: Future Outlook - Following the restructuring, Carbon Revolution plc is expected to cease any continuing equity interest in the Australian subsidiaries, leading to an orderly wind down and liquidation of the publicly-traded company [8]. - The company expresses gratitude to its stakeholders for their support during this transition [9].

Core Viewpoint - XORTX Therapeutics Inc. has announced a consolidation of its common shares at a ratio of one post-consolidation share for every five pre-consolidation shares, effective March 27, 2026, to comply with NASDAQ listing requirements [1][3]. Group 1: Share Consolidation Details - The consolidation has been approved by the TSX Venture Exchange and was ratified at the annual and special meeting of shareholders on March 24, 2026 [2]. - The number of issued and outstanding shares will decrease from 6,962,218 to approximately 1,392,444, with no fractional shares being issued [2]. - Fractional shares will either be canceled if less than half a share or rounded up to the nearest whole share if equal to or greater than half a share [2]. Group 2: Compliance and Trading Information - The consolidation aims to ensure compliance with NASDAQ's requirement for shares to trade above $1.00 for 10 consecutive days by April 13, 2026 [3]. - Post-consolidation shares will continue to trade under the symbol "XRTX" on both TSXV and NASDAQ, with a new CUSIP number of 98420Q405 [4]. - Trading on a post-consolidation basis is expected to commence on March 27, 2026 [4]. Group 3: Shareholder Communication - Shareholders of record as of the effective date will receive a letter of transmittal from TSX Trust Company with instructions for exchanging their shares [5].

Core Viewpoint - Golar LNG Limited has initiated a formal process to evaluate strategic alternatives aimed at accelerating its Floating Liquefied Natural Gas (FLNG) growth pipeline and maximizing shareholder value, with Goldman Sachs International appointed as the financial advisor [1][2]. Group 1: Strategic Review Process - The strategic review will comprehensively evaluate the Company's FLNG technology, long-term contract backlog, and growth pipeline, exploring alternatives such as a sale, merger, asset divestiture, or corporate structure optimization [2]. - The Company aims to identify solutions that unlock shareholder value and facilitate a faster rollout of its FLNG growth pipeline [2]. Group 2: Timeline and Outcomes - There is no set timetable for the conclusion of the strategic review, and there is no assurance that it will result in any specific transaction or strategic outcome [3].

Core Viewpoint - Marex Group plc has filed its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the SEC, highlighting its financial performance and operational details [1]. Company Overview - Marex Group plc (NASDAQ: MRX) is a diversified global financial services platform providing market access, infrastructure services, and essential liquidity across global commodity and financial markets [2]. - The company offers a comprehensive range of services including Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions, with a strong presence in metals, energy, and agricultural products [2]. - Marex has access to over 60 exchanges and serves more than 3,400 active clients, including major commodity producers, consumers, traders, banks, hedge funds, and asset managers [2]. - The company operates more than 50 offices worldwide and employs over 3,000 staff across Europe, Asia, and the Americas [2].

Core Viewpoint - Polyrizon Ltd., a pre-clinical-stage biotechnology company, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission [1] Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a hydrogel-based shield in the nasal cavity to protect against viruses and allergens [3] - The company's proprietary technology, Capture and Contain TM (C&C), utilizes naturally occurring building blocks to form a barrier in the nasal cavity, potentially acting as a "biological mask" [3] - Polyrizon is also developing its Trap and Target ™ (T&T) technology, focused on the nasal delivery of active pharmaceutical ingredients (APIs), which is currently in an earlier stage of pre-clinical development [3] Report Availability - The Annual Report on Form 20-F is accessible on the SEC's website and Polyrizon's Investor Relations website, with shareholders able to request copies free of charge [2]

Core Insights - Toppoint Holdings Inc. reported a revenue increase of 3.2% year-over-year for 2025, driven by strong growth in import freight and scrap metal transportation, despite a decline in waste paper revenue [6][10] - The company is focusing on long-term growth strategies, including expanding its business mix and investing in infrastructure and technology to enhance operational scale [2][4] Financial Performance - Total revenue for 2025 was $16,548,734, up from $16,039,513 in 2024, reflecting a $509,221 increase [6][10] - Cost of revenues rose to $16,051,009 in 2025, a 12.5% increase from $14,270,913 in 2024, leading to a gross profit of $497,725 and a gross margin of 3.0%, down from 11.0% in 2024 [7][11] - Selling, general and administrative expenses surged to $7,875,263 in 2025, a 226.2% increase from $2,414,351 in 2024, primarily due to public company costs and personnel expansion [8][11] - The net loss for 2025 was $(7,344,586), a significant decline from a net income of $174,871 in 2024, largely due to non-cash stock-based compensation [8][11] Revenue Breakdown - Import revenue increased by 36.0% to $4,837,876, with import loads rising by 54.7% to 6,275 [10][12] - Scrap metal revenue saw a substantial increase of 77.4% to $2,041,790, with waste metal loads increasing by 94.1% to 2,413 [10][12] - Waste paper revenue decreased by 14.5% to $9,153,668, reflecting ongoing softness in the market [12] Operational Highlights - The company expanded its domestic and international footprint, particularly in Ensenada, Mexico, and Texas, while enhancing capabilities in import drayage and refrigerated logistics [3][4] - Toppoint's operational foundation was strengthened following its NYSE American listing in January 2025 [3][4]

Core Insights - Dundee Corporation reported solid net earnings driven by significant investment gains in its mining portfolio and monetization transactions that improved its cash position and financial flexibility [1][2] - The company has entered a joint-venture agreement with Westhaven Gold, allowing it to earn a meaningful interest in the Shovelnose Gold Project and the Spences Bridge Gold Belt through staged expenditures [1][6] - The acquisition of Maritime Resources by New Found Gold in 2025 demonstrates Dundee's ability to identify exceptional assets and positions it for future growth opportunities [1][3] Financial Performance - For the fourth quarter of 2025, Dundee reported net earnings before taxes from mining investments of $205 million, a significant increase from a loss of $4.2 million in 2024 [5] - The total net earnings before taxes from mining investments for 2025 reached $353.4 million, compared to $61.6 million in 2024 [6][7] - The corporation recognized a gain of $102.3 million due to a change in accounting treatment for its investment in Magna Mining, reflecting a shift from equity method to fair value measurement [3][6] Investment Activities - Dundee sold 24.5 million units of New Found Gold for gross proceeds of $97.9 million, which included common shares and warrants [3] - The corporation recognized a $47.5 million gain from the sale of a net smelter royalty from the Borborema Gold Project, which will be recorded in the first quarter of 2026 [3][5] - The company reported a pre-tax loss of $11.3 million from the corporate and others segment in Q4 2025, primarily due to a decrease in the fair value of non-mining portfolio investments [8][9] Shareholder Value - Dundee ended 2025 with a strong cash position and no debt at the parent level, positioning itself for future cash flow generation [2] - The reported net earnings attributable to owners for Q4 2025 were $185.5 million, compared to a net loss of $8.2 million in 2024, with earnings per share of $1.88 [5][6] - For the full year 2025, net earnings attributable to owners reached $320.5 million, significantly up from $59.1 million in 2024, resulting in earnings per share of $3.27 [6][11]

Core Viewpoint - B2Gold Corp. announced positive exploration drilling results from the 2025 Back River Gold District exploration program in Nunavut, Canada, confirming significant resource potential and supporting resource reclassification and mine planning [1]. Exploration Drilling Results - High-grade mineralization was intersected at the Nuvuyak deposit, located 1,000 m west and down plunge of the Goose Main deposit [3]. - Infill drilling at the Goose Mine Llama deposit confirmed continuity of high-grade gold mineralization, with notable intersections including: - 41.95 grams per tonne (g/t) gold over 13.70 meters (m) from drill hole 25GSE702 [5] - 17.95 g/t gold over 38.20 m from drill hole 25GSE715Z1 [5] - 19.74 g/t gold over 18.80 m from drill hole 25GSE720Z1 [5] - The existing Indicated Mineral Resource estimate at Llama is 3.04 million tonnes grading 7.72 g/t gold, totaling 760,000 ounces of gold, while the Inferred Mineral Resource estimate is 1.79 million tonnes grading 11.00 g/t gold, totaling 637,000 ounces of gold [5]. 2025 Exploration Program Overview - B2Gold allocated a total budget of $32 million for the 2025 exploration program, focusing on improving deposit knowledge and identifying new mineralization zones [7]. - A total of 28,599 m of drilling was completed in 140 diamond drill holes, with 19,736 m at the Goose Mine and near-mine targets, and 8,863 m at regional targets [8]. Goose Mine and Regional Exploration - The Goose Mine consists of six main deposits, with ongoing mining operations at the Umwelt deposit and Llama scheduled as the next to be mined [9]. - Significant drill results from the Wing deposit included: - 8.33 g/t gold over 8.40 m from drill hole 25GSE734 [21] - 13.41 g/t gold over 8.50 m from drill hole 25GSE738 [21]. - Regional exploration drilling at the George Project returned results of 10.42 g/t gold over 5.65 m from drill hole 25GRL224 [23]. Future Exploration Plans - For 2026, B2Gold has budgeted $46 million for exploration, with $24 million for the Goose Mine and $22 million for regional exploration [31]. - The 2026 program will target extensions of the Llama deposit and follow-up drilling at significant results from the Nuvuyak-Mammoth-Hook targets and the Wing deposit [32].

Core Points - CNH Industrial has announced the date and details for its 2026 Annual General Meeting (AGM), which will take place on May 8, 2026, in Amsterdam, Netherlands, with a live webcast available [1] - The company has declared a cash dividend of USD $0.10 per share, pending shareholder approval, with a record date of May 21, 2026, and expected payment on May 29, 2026 [3] - CNH Industrial focuses on innovation, sustainability, and productivity, providing a wide range of agricultural and construction equipment through its various brands [4] Company Overview - CNH Industrial is a global leader in equipment, technology, and services, with a mission centered on breaking new ground through innovation and efficiency [4] - The company employs over 34,000 individuals and emphasizes a diverse and inclusive workplace aimed at empowering customers [5] - CNH's brands include Case IH, New Holland, CASE, STEYR, Raven, Hemisphere, Flexi-Coil, Miller, and Eurocomach, each specializing in different aspects of agriculture and construction [4][5] AGM Materials - The AGM materials, including audited financial statements, are available for shareholders to view and download on the company's website, with options for requesting hard copies [2]

Core Viewpoint - COSCIENS Biopharma Inc. has reported its financial and operational results for the fourth quarter and full year of 2025, highlighting significant restructuring efforts and strategic decisions aimed at improving financial stability and shareholder value [1][5]. Corporate Update - Following the reconstitution of the Board on May 30, 2025, the Company has initiated a comprehensive restructuring plan to streamline operations and enhance efficiency, resulting in a reduced burn rate and alignment with market conditions [2]. - The Company has ceased funding its German subsidiaries, leading to an application for insolvency proceedings, which is expected to generate approximately $1.9 million in annualized cost savings [3]. - The Company plans to further reduce administrative costs by terminating or suspending public reporting obligations under the Securities Exchange Act, while continuing to meet Canadian securities laws [4]. Financial Summary - As of December 31, 2025, the Company had $7.3 million in cash and cash equivalents [6]. - The consolidated net loss for Q4 2025 was $2.2 million, a decrease from $6.7 million in Q4 2024, primarily due to reductions in impairment expenses, R&D costs, income tax expense, and SG&A expenses [6][12]. - For FY 2025, the consolidated net loss was $10.4 million, down from $15.3 million in FY 2024, attributed to decreases in impairment and R&D costs [6][12]. - Total revenue for Q4 2025 was $1.8 million, down from $3.3 million in Q4 2024, mainly due to declines in pharmaceutical revenue and sales of active ingredients [7][12]. - Total revenue for FY 2025 was $7.5 million, compared to $9.6 million in FY 2024, reflecting a decrease primarily in active ingredient sales and pharmaceutical revenue [12]. Future Outlook - The Company is committed to pursuing additional cost-savings, achieving profitability, and exploring opportunities to enhance shareholder value through organic growth and strategic transactions [5].